Total Payments
$1.5M
2024 Payments
$110,349
Companies
40
Transactions
1,626
Medicare Patients
3,594
Medicare Billing
$967,036
Payment Breakdown by Category
Other$1.0M (67.7%)
Consulting$237,593 (15.6%)
Travel$202,451 (13.3%)
Food & Beverage$40,365 (2.6%)
Research$11,398 (0.7%)
Education$108.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $952,129 | 357 | 62.5% |
| Consulting Fee | $237,593 | 88 | 15.6% |
| Travel and Lodging | $202,451 | 522 | 13.3% |
| Honoraria | $56,765 | 51 | 3.7% |
| Food and Beverage | $40,365 | 573 | 2.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $22,500 | 5 | 1.5% |
| Unspecified | $11,398 | 24 | 0.7% |
| Education | $108.42 | 6 | 0.0% |
Payments by Type
General
$1.5M
1,602 transactions
Research
$11,398
7 transactions
Ownership
$0
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $333,264 | 342 | $0 (2024) |
| Janssen Biotech, Inc. | $150,821 | 257 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $144,450 | 150 | $0 (2024) |
| Astellas Pharma US Inc | $141,101 | 114 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $119,217 | 111 | $0 (2024) |
| Amgen Inc. | $100,107 | 88 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $88,677 | 63 | $0 (2024) |
| Merck Sharp & Dohme LLC | $81,418 | 56 | $0 (2023) |
| PFIZER INC. | $71,731 | 66 | $0 (2024) |
| SN Holdings, LLC | $62,815 | 98 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110,349 | 116 | Sumitomo Pharma America, Inc. ($28,104) |
| 2023 | $154,327 | 149 | Bayer Healthcare Pharmaceuticals Inc. ($36,840) |
| 2022 | $208,449 | 216 | AstraZeneca Pharmaceuticals LP ($49,046) |
| 2021 | $156,780 | 150 | AstraZeneca Pharmaceuticals LP ($55,134) |
| 2020 | $162,223 | 147 | Bayer HealthCare Pharmaceuticals Inc. ($36,536) |
| 2019 | $141,512 | 198 | Bayer HealthCare Pharmaceuticals Inc. ($53,738) |
| 2018 | $270,590 | 318 | Bayer HealthCare Pharmaceuticals Inc. ($72,011) |
| 2017 | $319,081 | 332 | Bayer HealthCare Pharmaceuticals Inc. ($56,358) |
All Payment Transactions
1,626 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,020.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $673.48 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | Cash or cash equivalent | $565.14 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $5.25 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $47.85 | General |
| Category: Oncology | ||||||
| 11/26/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/22/2024 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $55.72 | General |
| 11/22/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $37.70 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/21/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $136.11 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $42.31 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $164.57 | General |
| Category: Oncology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $83.17 | General |
| Category: HORMONE THERAPY | ||||||
| 11/07/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $18.46 | General |
| Category: HORMONE THERAPY | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $114.10 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $142.08 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/28/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $115.61 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/28/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $27.11 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| 10/24/2024 | UROGEN PHARMA, INC. | — | Honoraria | Cash or cash equivalent | $2,040.00 | General |
| 10/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $140.91 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PROTOCOL FOR CONTINUED PATIENT ACCESS TO STUDY DRUG | Eli Lilly and Company | $5,328 | 1 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,870 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 781 | 9,833 | $618,061 | $212,128 |
| 2022 | 17 | 877 | 14,475 | $854,547 | $294,291 |
| 2021 | 22 | 900 | 14,141 | $801,993 | $261,537 |
| 2020 | 27 | 1,036 | 11,273 | $675,358 | $199,080 |
Total Patients
3,594
Total Services
49,722
Medicare Billing
$967,036
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 38 | 7,380 | $287,820 | $133,005 | 46.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 35 | 267 | $88,110 | $35,622 | 40.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 169 | $64,220 | $15,065 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 114 | 144 | $38,880 | $8,718 | 22.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 88 | 99 | $68,581 | $5,678 | 8.3% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 11 | 14 | $9,730 | $2,613 | 26.9% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Office | 2023 | 13 | 14 | $9,825 | $2,311 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $10,968 | $2,096 | 19.1% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 20 | 37 | $8,459 | $1,759 | 20.8% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 13 | 14 | $5,260 | $1,407 | 26.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 34 | 44 | $4,620 | $1,145 | 24.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 74 | $6,068 | $800.78 | 13.2% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 75 | 79 | $4,819 | $591.31 | 12.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 85 | 93 | $1,395 | $317.13 | 22.7% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 13 | 13 | $1,469 | $301.08 | 20.5% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 15 | 15 | $1,077 | $284.40 | 26.4% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 16 | 1,313 | $1,313 | $159.84 | 12.2% |
| 51784 | Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Office | 2023 | 13 | 14 | $4,843 | $158.88 | 3.3% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 16 | 16 | $256.00 | $63.04 | 24.6% |
| 51741 | Electronic assessment of bladder emptying | Office | 2023 | 13 | 14 | $348.00 | $33.42 | 9.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 45 | 11,520 | $426,420 | $194,979 | 45.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 42 | 360 | $142,740 | $48,412 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 200 | $73,375 | $17,356 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 158 | 207 | $53,970 | $12,429 | 23.0% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 112 | 119 | $79,373 | $6,728 | 8.5% |
About Dr. Bryan Mehlhaff, MD
Dr. Bryan Mehlhaff, MD is a Urology healthcare provider based in Springfield, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518978204.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bryan Mehlhaff, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $110,349 received in 2024. These payments were reported across 1,626 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($952,129).
As a Medicare-enrolled provider, Mehlhaff has provided services to 3,594 Medicare beneficiaries, totaling 49,722 services with total Medicare billing of $967,036. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Springfield, OR
- Active Since 08/10/2006
- Last Updated 09/28/2022
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1518978204
Products in Payments
- Xofigo (Drug) $205,252
- PROVENGE (Drug) $159,867
- LYNPARZA (Drug) $141,107
- Nubeqa (Drug) $121,615
- Erleada (Drug) $119,554
- XTANDI (Drug) $94,385
- ERLEADA (Drug) $83,468
- Xtandi (Drug) $73,195
- XGEVA (Biological) $55,206
- ORGOVYX (Drug) $51,808
- Prolia (Biological) $44,901
- KEYTRUDA (Biological) $37,984
- TALZENNA (Drug) $25,257
- PYLARIFY (Drug) $21,252
- DARZALEX (Biological) $19,154
- PLUVICTO (Drug) $11,764
- ELIGARD (Drug) $7,580
- ZYTIGA (Drug) $7,490
- YONSA (Drug) $7,230
- Bavencio (Biological) $6,311
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Springfield
Kevin Mcvary, Md, MD
Urology — Payments: $405,504
Urology $405,504
Bradley Schwartz, M.d, M.D
Urology — Payments: $105,537
Urology $105,537
Robert Nadler, Md, MD
Urology — Payments: $93,691
Urology $93,691
Kevin Krughoff
Urology — Payments: $54,104
Urology $54,104
Dr. Eric Espinosa
Urology — Payments: $23,023
Urology $23,023
Michael Zavaski, Md, MD
Urology — Payments: $22,511
Urology $22,511